Stock KYMR KYMERA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Real-time Estimate Cboe BZX
Other stock markets
 12:48:30 2024-06-05 pm EDT 		5-day change 1st Jan Change
32.86 USD +2.86% Intraday chart for Kymera Therapeutics, Inc. +1.35% +29.34%
Jun. 01 Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting CI
May. 22 Kymera Therapeutics, Inc. Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kymera Therapeutics : Corporate Presentation, June 2024
PU
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
AQ
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
GL
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
CI
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
GL
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
GL
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
AQ
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
GL
Kymera Therapeutics, Inc. Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
CI
Transcript : Kymera Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 04:20 PM
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
GL
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of Stat3 Degrader KT-333 At EHA Annual Meeting
CI
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
GL
Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53
MT
Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises
MT
Kymera Therapeutics : Corporate Presentation, May 2024
PU
Transcript : Kymera Therapeutics, Inc., Q1 2024 Earnings Call, May 02, 2024
Kymera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
GL
Kymera Therapeutics, Inc. Provides Business Highlights and Updates on Its Pipeline of Protein Degraders
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KYMR Stock
  4. News Kymera Therapeutics, Inc.